Evidence and service information checked, October 2026.
Topical finasteride is often marketed as a way to treat male pattern hair loss without taking a tablet. The important distinction is that applying a medicine to the scalp can reduce systemic exposure, but does not guarantee that it stays on the scalp. The product, dose, evidence and person using it all matter.
Is topical finasteride safer than finasteride tablets?
A particular topical finasteride spray produced substantially lower blood concentrations than oral finasteride in a 24-week trial, while improving hair counts compared with placebo. That does not prove that every topical or compounded formulation is safer, that long-term risks are absent, or that sexual and psychiatric side effects cannot occur.
Finasteride reduces the conversion of testosterone to dihydrotestosterone, or DHT. DHT contributes to follicle miniaturisation in androgenetic alopecia. Topical treatment aims to deliver the drug where it is needed while limiting exposure elsewhere. That is a rationale to test, not a guarantee of zero absorption.
The decision in brief
- Establish that the hair loss is androgenetic alopecia before choosing a DHT-targeting treatment.
- Ask about the exact formulation and dose, not simply whether it is "topical".
- Lower average systemic exposure does not mean no systemic risk.
- A compounded preparation is not interchangeable with the product studied in a trial.
- Ask how adverse effects, transfer to other people and follow-up will be managed.
Request a hair-loss consultation if you need a diagnosis-led plan. This article does not imply that The London PRP Clinic supplies every medicine discussed.
What did the topical finasteride trial actually show?
A phase III randomised trial enrolled 458 men with androgenetic alopecia; 323 completed the study. At 24 weeks, the adjusted change in target-area hair count was about 20.2 hairs with the topical spray versus 6.7 with placebo. The oral reference arm had a numerically similar hair-count improvement.
Blood concentrations of finasteride were more than 100 times lower with the topical formulation than with oral treatment. Average serum DHT fell by around 34.5% with the topical treatment and 55.6% with oral finasteride.
Those results support efficacy for the studied formulation and show that the topical product still had a systemic hormonal effect. They do not establish formal equivalence with tablets, prove superior long-term safety or predict what a different concentration, vehicle or amount will do.
The trial lasted six months, enrolled selected men and had industry involvement. Hair-count changes in a defined target area are not the same as a guarantee of visible restoration across the entire scalp. The published trial is useful evidence, but a prescription decision needs more than its headline.
Can topical finasteride cause systemic side effects?
Yes, systemic absorption is possible. In April 2025, the US Food and Drug Administration warned about potential risks associated with compounded topical finasteride. It described reports including sexual symptoms, mood symptoms and other problems, and warned about accidental transfer to other people.
The FDA received 32 adverse-event reports associated with compounded topical products between 2019 and 2024. These reports are a safety signal, not a measured side-effect rate: they do not tell us how many people used the products or prove that finasteride caused every reported symptom.
The FDA alert concerns the US compounding context. It does not establish the licensing status of a UK product. Ask a UK prescriber or pharmacist to explain the actual product's regulatory status, supply route and information leaflet.
The UK MHRA has separately warned about psychiatric and sexual side effects with finasteride and notes that sexual side effects may persist after treatment stops. Do not interpret a topical label or a low dose as a promise that these concerns are irrelevant.
If you develop mood changes, sexual symptoms or another suspected reaction, contact the prescriber promptly for advice. Suicidal thoughts or an immediate risk of self-harm require urgent help. Call 999 if you are in immediate danger. Do not wait for a routine hair-clinic reply.
Why the bottle and instructions matter
Two products with the same ingredient can deliver different amounts. Concentration, spray volume, treated area, frequency, vehicle and scalp condition can affect exposure. A prescription that says only "topical finasteride" is not enough information for an informed comparison.
Ask for the exact concentration, the amount per application, where to apply it and what to do if your scalp is inflamed. Do not use extra to accelerate results, apply it to broken skin without advice or copy another person's regimen.
If finasteride is combined with minoxidil, ask which ingredient is intended to do what and which can cause a particular adverse effect. A combination can make it harder to identify the cause of irritation or another symptom. More ingredients do not automatically mean better evidence.
What about pregnancy and transfer to other people?
Finasteride exposure is a concern in pregnancy because of potential harm to a male fetus. Accidental transfer through treated skin, hands or surfaces needs considering with topical products.
Ask the prescriber about washing hands, drying time, contact precautions and what to do after accidental exposure. Follow the actual product instructions. Do not assume instructions for one preparation apply to another, and do not share a prescription with a partner.
People who are pregnant, may become pregnant or are breastfeeding should not use someone else's finasteride treatment. Advice about household contact is part of prescribing, not an optional afterthought.
Is topical finasteride right for every type of hair loss?
No. Sudden shedding, smooth patches, scaling, pain, pustules or a shiny scarred area may need a different assessment. Finasteride does not correct iron deficiency, remove traction or treat a hair-pulling disorder simply because thinning is visible.
A useful consultation reviews the pattern, time course, scalp, medicines and relevant history. Trichoscopy can help assess miniaturisation and scalp findings. Tests are chosen when the history suggests a reason, not added indiscriminately.
Ask for an assessment before buying a treatment bundle. You should leave knowing the working diagnosis, sensible options and what would change the plan.
Where does PRP fit?
PRP is a separate procedure, not a topical-finasteride antidote and not proof that medication is unnecessary. It may be discussed for selected people with androgenetic hair loss after diagnosis, with uncertainty about response, protocols and maintenance explained.
It does not treat a medicine's systemic side effects and should not be sold as a way to make an unsuitable prescription safe. A thoughtful plan can include medication, a procedure, neither, or referral depending on your needs and preferences.
As checked in October 2026, The London PRP Clinic lists a £150, 30-minute consultation including scalp assessment and trichoscopy, with £50 credited towards treatment under the listed arrangement. The same page lists hair PRP at £450 per session. Confirm suitability, current terms and availability before booking; a consultation is not a commitment to a course.
Questions to bring to your prescriber
- What diagnosis are we treating, and what benefit is realistic?
- What exact formulation and dose are you recommending?
- What evidence applies to this product rather than a different spray?
- What systemic and local adverse effects should I watch for?
- How do I prevent transfer to other people?
- When will we review progress, and what happens if I stop?
Is topical finasteride completely side-effect free?
No. A topical route does not establish that. Local reactions, systemic absorption and transfer risk need discussing.
Can I use a stronger concentration for faster results?
Do not increase strength or application amount without the prescriber. The evidence does not justify assuming that more is better or safer.
Can I buy it because I cannot tolerate tablets?
A tablet-related adverse effect is a reason for an individual review, not an automatic green light for topical treatment.
Contact The London PRP Clinic for a diagnosis-led hair assessment, not a guaranteed prescription or result.
Sources
- Piraccini and colleagues: Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia, phase III randomised trial.
- FDA: Potential risks associated with compounded topical finasteride products, April 2025.
- MHRA: Finasteride reminder of psychiatric and sexual side-effect risks, including persistence after discontinuation.
General information only. Treatment requires an individual clinical assessment and the instructions for the product actually supplied.